Physician profile
David E Mee
NPI 1578872099
$9,348.72
in general payments reported to CMS, 2019-2025
24 companies · $2,098 in 2025
The $2,098 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $1,680 · 2023: $2,124 · 2024: $2,453 · 2025: $2,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,413 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,413.29 |
| Education | $261.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,141.01 | 2021-2025 | |
| Janssen Biotech, INC. | $1,510.02 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $835.05 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $728.54 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $660.67 | 2021-2025 | |
| Amgen INC. | $628.01 | 2021-2025 | Otezla |
| Ucb, INC. | $485.93 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $461.57 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $456.64 | 2021-2025 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $231.58 | 2021-2025 | Blu-U, Odomzo, Ilumya |
| Incyte Corporation | $205.25 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $158.01 | 2024-2025 | Aklief, Oracea |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Leo Pharma INC. | $119.91 | 2022-2025 | Anzupgo, Adbry |
| Arcutis Biotherapeutics, INC. | $112.48 | 2024-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $95.57 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Dermavant Sciences, INC. | $73.16 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.08 | 2021-2024 | Jublia, Arazlo |
| Blueprint Medicines Corporation | $47.94 | 2022-2023 | |
| Organon LLC | $47.77 | 2025 | Vtama |
| Biofrontera INC. | $34.52 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $24.41 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.61 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.